According to the company, preliminary clinical trials gave a positive result.
Moderna Inc said Monday that its experimental COVID-19 vaccine had developed antibodies that can neutralize a new coronavirus in patients at an early stage of clinical trials.
Preliminary results of a study conducted by the National Institutes of Health showed that the levels of antibodies were similar to those present in blood samples of people who recovered from COVID-19.
The study participants were given three different doses of the vaccine. As noted by Moderna, the dependence of the growth of the body’s immunity on the volume of the treatment was found.